bs-6060R-HRP [Conjugated Primary Antibody]
NARC1 Polyclonal Antibody, HRP Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: NARC1

Immunogen Range: 231-330/692


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 255738

Swiss Prot: Q8NBP7

Source: KLH conjugated synthetic peptide derived from human PCSK9/NARC1

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments (PubMed:18039658). Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation (PubMed:18799458, PubMed:17461796, PubMed:18197702, PubMed:22074827). Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway (PubMed:18660751). Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Conjugation: HRP

Excitation/ Emission: N/A

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)

Predicted Molecular Weight: 57


Cross Reactive Species: Human
Mouse
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Tanaka H et al. Proprotein Convertase Subtilisin/Kexin Type 9 Is Associated with Degenerating Adipocytes in Abdominal Aortic Aneurysm.(2018)J Oleo Sci.Oct 11;67(10):1355-1360.Read more>>
  • Wei Zou. et al. Imperatae rhizoma-Hedyotis diffusa Willd. herbal pair alleviates nephrotic syndrome by integrating anti-inflammatory and hypolipidaemic effects. Phytomedicine. 2021 Sep;90:153644Read more>>
  • R. Yang. et al. Xinnaokang improves cecal microbiota and lipid metabolism to target atherosclerosis. Lett Appl Microbiol. 2021 Dec;73(6):779-792Read more>>
  • Zhu, Wenqiang. et al. Metformin Ameliorates Hepatic Steatosis induced by olanzapine through inhibiting LXR_/PCSK9 pathway. SCI REP-UK. Sci Rep-Uk. 2022 Apr;12(1):1-13Read more>>
  • Huiming Hu. et al. The Hypolipidemic Effect of Hawthorn Leaf Flavonoids through Modulating Lipid Metabolism and Gut Microbiota in Hyperlipidemic Rats.. EVID-BASED COMPL ALT. 2022 Nov;2022:3033311-3033311Read more>>
  • Xie Jingke. et al. Precise genome editing of the Kozak sequence enables bidirectional and quantitative modulation of protein translation to anticipated levels without affecting transcription. NUCLEIC ACIDS RES. 2023 AugRead more>>
  • Yang Yang. et al. PCSK9 inhibitor effectively alleviated cognitive dysfunction in a type 2 diabetes mellitus rat model. PEERJ. 2024 Aug;12:e17676Read more>>
VALIDATION IMAGES